|
US7048906B2
(en)
|
1995-05-17 |
2006-05-23 |
Cedars-Sinai Medical Center |
Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
|
|
EP1950224A3
(en)
|
1998-03-09 |
2008-12-17 |
Zealand Pharma A/S |
Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
|
|
SE9801571D0
(sv)
|
1998-05-05 |
1998-05-05 |
Wapharm Ab |
Melanokortin-1-receptorselektiva föreningar
|
|
US6444788B1
(en)
|
1999-03-15 |
2002-09-03 |
Novo Nordisk A/S |
Ion exchange chromatography of GLP-1, analogs and derivatives thereof
|
|
US6528486B1
(en)
|
1999-07-12 |
2003-03-04 |
Zealand Pharma A/S |
Peptide agonists of GLP-1 activity
|
|
ATE396738T1
(de)
|
2000-09-18 |
2008-06-15 |
Sanos Bioscience As |
Verwendung von glp-2-peptiden
|
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
|
US7259233B2
(en)
|
2000-12-13 |
2007-08-21 |
Eli Lilly And Company |
Chronic treatment regimen using glucagon-like insulinotropic peptides
|
|
CN1162446C
(zh)
*
|
2001-05-10 |
2004-08-18 |
上海华谊生物技术有限公司 |
促胰岛素分泌肽衍生物
|
|
CN1158304C
(zh)
*
|
2001-05-10 |
2004-07-21 |
上海华谊生物技术有限公司 |
蛙皮抗菌肽衍生物
|
|
DK1412384T3
(da)
|
2001-06-28 |
2008-04-28 |
Novo Nordisk As |
Stabil formulering af modificeret GLP-1
|
|
ATE408414T1
(de)
|
2001-07-31 |
2008-10-15 |
Us Gov Health & Human Serv |
Glp 1 exendin 4 peptidanaloga und deren verwendungen
|
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
|
US8129504B2
(en)
|
2001-08-30 |
2012-03-06 |
Biorexis Technology, Inc. |
Oral delivery of modified transferrin fusion proteins
|
|
NZ532427A
(en)
|
2001-09-24 |
2008-07-31 |
Imp Innovations Ltd |
Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
|
|
WO2003059378A2
(en)
|
2001-12-29 |
2003-07-24 |
Novo Nordisk A/S |
Combined use of a glp-1 compound and another drug for treating dyslipidemia
|
|
CA2472882A1
(en)
|
2002-01-10 |
2003-07-17 |
Imperial College Innovations Ltd |
Use of pyy and glp-1, or an agonist thereof, for the modification of feeding behaviour
|
|
US7105489B2
(en)
|
2002-01-22 |
2006-09-12 |
Amylin Pharmaceuticals, Inc. |
Methods and compositions for treating polycystic ovary syndrome
|
|
JP2005535569A
(ja)
*
|
2002-04-04 |
2005-11-24 |
ノボ・ノルデイスク・エー／エス |
Ｇｌｐ−１アゴニスト及び心臓血管合併症
|
|
ES2327328T3
(es)
*
|
2002-07-04 |
2009-10-28 |
Zealand Pharma A/S |
Glp-1 y procedimientos para el tratamiento de la diabetes.
|
|
CA2497794A1
(en)
*
|
2002-09-06 |
2004-03-18 |
Bayer Pharmaceuticals Corporation |
Modified glp-1 receptor agonists and their pharmacological methods of use
|
|
US7273921B2
(en)
|
2002-09-25 |
2007-09-25 |
Novo Nordisk A/S |
Method for producing acylated peptides
|
|
RU2376314C2
(ru)
*
|
2002-10-02 |
2009-12-20 |
Зилэнд Фарма А/С |
Стабилизированные соединения эксендина-4
|
|
EP1559724A4
(en)
*
|
2002-10-11 |
2006-02-08 |
Sanwa Kagaku Kenkyusho Co |
GLP-1 DERIVATIVES AND TRANSMUCOSAL ABSORPTION PREPARATIONS THEREOF
|
|
US6818721B2
(en)
|
2002-12-02 |
2004-11-16 |
Rpo Pty Ltd. |
Process for producing polysiloxanes and use of the same
|
|
EP1688148A1
(en)
*
|
2002-12-03 |
2006-08-09 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
|
AU2003283216A1
(en)
*
|
2002-12-03 |
2004-06-23 |
Novo Nordisk A/S |
Combination treatment using exendin-4 and thiazolidinediones
|
|
GB0300571D0
(en)
|
2003-01-10 |
2003-02-12 |
Imp College Innovations Ltd |
Modification of feeding behaviour
|
|
EP1626981A4
(en)
*
|
2003-03-04 |
2006-11-22 |
Biorexis Pharmaceutical Corp |
PROTEINS PROTECTED AGAINST DIPEPTIDYLPEPTIDASE
|
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
|
ES2425221T3
(es)
|
2003-05-30 |
2013-10-14 |
Amylin Pharmaceuticals, Llc |
Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
|
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
|
US7008957B2
(en)
|
2003-07-25 |
2006-03-07 |
Sanofi-Aventis Deutschland Gmbh |
Bicyclic cyanoheterocycles, process for their preparation and their use as medicaments
|
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
|
CN100444898C
(zh)
*
|
2003-09-19 |
2008-12-24 |
诺沃挪第克公司 |
治疗肽的清蛋白结合型衍生物
|
|
EP1667724A2
(en)
*
|
2003-09-19 |
2006-06-14 |
Novo Nordisk A/S |
Albumin-binding derivatives of therapeutic peptides
|
|
RU2401276C2
(ru)
*
|
2003-09-19 |
2010-10-10 |
Ново Нордиск А/С |
Производные глюкагон-подобного пептида-1 (glp-1)
|
|
TW200526254A
(en)
*
|
2003-09-19 |
2005-08-16 |
Novo Nordisk As |
Novel GLP-1 derivatives
|
|
US20060287221A1
(en)
|
2003-11-13 |
2006-12-21 |
Novo Nordisk A/S |
Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
|
|
EP1684793B1
(en)
*
|
2003-11-13 |
2011-09-21 |
Novo Nordisk A/S |
Pharmaceutical composition comprising an insulinotropic glp-1(7-37) analogue, asp(b28)-insulin, and a surfactant
|
|
CN104826116A
(zh)
|
2003-11-20 |
2015-08-12 |
诺沃挪第克公司 |
对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
|
|
WO2005056036A2
(en)
|
2003-12-09 |
2005-06-23 |
Novo Nordisk A/S |
Regulation of food preference using glp-1 agonists
|
|
EP1701731A4
(en)
*
|
2003-12-12 |
2009-08-05 |
Einstein Coll Med |
GLP-1 (9-36) METHOD AND COMPOSITIONS
|
|
ATE461217T1
(de)
|
2003-12-18 |
2010-04-15 |
Novo Nordisk As |
Glp-1-verbindungen
|
|
EP2417980A1
(en)
|
2004-02-11 |
2012-02-15 |
Amylin Pharmaceuticals Inc. |
Hybrid polypeptides with selectable properties
|
|
US8076288B2
(en)
|
2004-02-11 |
2011-12-13 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides having glucose lowering activity
|
|
CN1318587C
(zh)
*
|
2004-04-30 |
2007-05-30 |
成都芝田生物工程有限公司 |
酰胺化Exendin－4多肽的重组制备方法
|
|
US8410047B2
(en)
|
2004-06-11 |
2013-04-02 |
Novo Nordisk A/S |
Counteracting drug-induced obesity using GLP-1 agonists
|
|
DE102004043153B4
(de)
*
|
2004-09-03 |
2013-11-21 |
Philipps-Universität Marburg |
Erfindung betreffend GLP-1 und Exendin
|
|
AU2012202855B2
(en)
*
|
2004-09-03 |
2015-02-26 |
Philipps-Universitat Marburg |
GLP-1 and exendin related invention
|
|
US7893017B2
(en)
|
2004-10-07 |
2011-02-22 |
Novo Nordisk A/S |
Protracted GLP-1 compounds
|
|
WO2006037811A2
(en)
|
2004-10-07 |
2006-04-13 |
Novo Nordisk A/S |
Protracted exendin-4 compounds
|
|
JP5248113B2
(ja)
*
|
2004-11-12 |
2013-07-31 |
ノヴォ ノルディスク アー／エス |
ペプチドの安定な処方
|
|
DE102004058306A1
(de)
*
|
2004-12-01 |
2006-07-27 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Carboxy-terminal amidierten Peptiden
|
|
ES2541633T3
(es)
|
2005-01-14 |
2015-07-22 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Exendinas modificadas y usos de las mismas
|
|
US8716221B2
(en)
|
2005-01-14 |
2014-05-06 |
Wuxi Grandchamp Pharmaceutical Technology Co., Ltd. |
Modified exendins and uses thereof
|
|
WO2006086769A2
(en)
|
2005-02-11 |
2006-08-17 |
Amylin Pharmaceuticals, Inc. |
Gip analog and hybrid polypeptides with selectable properties
|
|
WO2006096565A2
(en)
*
|
2005-03-04 |
2006-09-14 |
Curedm Inc. |
Methods and pharmaceutical compositions for treating type 1 diabetes mellitus and other conditions
|
|
MX2007011307A
(es)
|
2005-03-18 |
2007-10-08 |
Novo Nordisk As |
Compuestos de glp-1 extendidos.
|
|
TWI372629B
(en)
*
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
|
WO2006097535A2
(en)
*
|
2005-03-18 |
2006-09-21 |
Novo Nordisk A/S |
Peptide agonists of the glucagon family with secretin like activity
|
|
CN101171262B
(zh)
|
2005-05-04 |
2012-06-27 |
西兰制药公司 |
胰高血糖素样肽-2(glp-2)类似物
|
|
EP2295066B1
(en)
|
2005-05-25 |
2016-04-27 |
CureDM Group Holdings, LLC |
Peptides, derivatives and analogs thereof, and methods of using same
|
|
EP2330125A3
(en)
|
2005-08-11 |
2012-12-12 |
Amylin Pharmaceuticals, Inc. |
Hybrid polypeptides with selectable properties
|
|
EP2330124B1
(en)
|
2005-08-11 |
2015-02-25 |
Amylin Pharmaceuticals, LLC |
Hybrid polypeptides with selectable properties
|
|
SI1919947T1
(sl)
|
2005-08-26 |
2013-06-28 |
Abbvie Inc. |
Terapevtsko aktivni alfa-msh analogi
|
|
DE102006031955A1
(de)
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Verfahren zur Herstellung von Insulinanaloga mit dibasischem B-Kettenende
|
|
DE102006031962A1
(de)
|
2006-07-11 |
2008-01-17 |
Sanofi-Aventis Deutschland Gmbh |
Amidiertes Insulin Glargin
|
|
ES2371495T3
(es)
|
2006-07-24 |
2012-01-03 |
Biorexis Pharmaceutical Corporation |
Proteínas de fusión de exendina.
|
|
EP2061767B1
(de)
|
2006-08-08 |
2014-12-17 |
Sanofi |
Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
|
|
BRPI0716134A2
(pt)
|
2006-09-07 |
2013-09-17 |
Nycomed Gmbh |
tratamento de combinaÇço para diabetes mellitus
|
|
NZ576260A
(en)
|
2006-11-08 |
2012-04-27 |
Zealand Pharma As |
GLUCAGON-LIKE-PEPTIDE-2 (GLP-2) ANALOGUES comprising one of more substitutions as compared to h[Gly2]GLP-2
|
|
JP2010043001A
(ja)
*
|
2006-11-09 |
2010-02-25 |
Sanwa Kagaku Kenkyusho Co Ltd |
Ｇｌｐ−１誘導体とその用途
|
|
WO2008064306A2
(en)
|
2006-11-22 |
2008-05-29 |
Curedm, Inc. |
Methods and compositions relating to islet cell neogenesis
|
|
TWI428346B
(zh)
|
2006-12-13 |
2014-03-01 |
Imp Innovations Ltd |
新穎化合物及其等對進食行為影響
|
|
RU2413528C2
(ru)
|
2007-01-18 |
2011-03-10 |
Открытое Акционерное Общество "Валента Фармацевтика" |
Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
|
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
WO2008098693A2
(en)
*
|
2007-02-16 |
2008-08-21 |
Bayer Healthcare Ag |
Convergent synthesis of glp-1
|
|
EA021544B1
(ru)
|
2007-06-04 |
2015-07-30 |
Бен-Гурион Юниверсити Оф Дзе Негев Рисерч Энд Дивелопмент Оторити |
Триарильные соединения и фармацевтические композиции, их содержащие
|
|
WO2008152403A1
(en)
|
2007-06-15 |
2008-12-18 |
Zealand Pharma A/S |
Glucagon analogues
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
PT2193142E
(pt)
|
2007-08-30 |
2015-04-22 |
Curedm Group Holdings Llc |
Composições e procedimentos de utilização de peptídeos pro-ilhota e seus análogos
|
|
WO2009030738A1
(en)
*
|
2007-09-05 |
2009-03-12 |
Novo Nordisk A/S |
Glucagon-like peptide-1 derivatives and their pharmaceutical use
|
|
ES2550363T3
(es)
|
2007-09-05 |
2015-11-06 |
Novo Nordisk A/S |
Derivados truncados de GLP-1 y su uso terapéutico
|
|
CA2703113A1
(en)
|
2007-10-27 |
2009-04-30 |
F. Hoffmann-La Roche Ag |
Insulinotropic peptide synthesis using solid and solution phase combination techniques
|
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
|
CA2705821A1
(en)
|
2007-11-16 |
2009-05-22 |
Novo Nordisk A/S |
Pharmaceutical compositions containing insulin and an insulinotropic peptide
|
|
DE102008003566A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
DE102008025007A1
(de)
|
2008-05-24 |
2009-11-26 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
CN101970476B
(zh)
|
2008-01-09 |
2014-08-27 |
塞诺菲-安万特德国有限公司 |
具有超延迟时效特征的胰岛素衍生物
|
|
DE102008025008A1
(de)
|
2008-05-24 |
2009-11-26 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
DE102008003568A1
(de)
|
2008-01-09 |
2009-07-16 |
Sanofi-Aventis Deutschland Gmbh |
Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
|
|
AU2009203809B2
(en)
|
2008-01-09 |
2013-07-25 |
Sanofi-Aventis Deutschland Gmbh |
Novel insulin derivatives having an extremely delayed time-action profile
|
|
EA020326B9
(ru)
*
|
2008-06-17 |
2015-03-31 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Агонисты смешанного действия на основе глюкозозависимого инсулинотропного пептида для лечения нарушений обмена веществ и ожирения
|
|
JP2011526303A
(ja)
|
2008-06-27 |
2011-10-06 |
デューク ユニバーシティ |
エラスチン様ペプチドを含む治療剤
|
|
US8470841B2
(en)
|
2008-07-09 |
2013-06-25 |
Sanofi |
Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
|
|
MX2011000847A
(es)
|
2008-08-06 |
2011-02-25 |
Novo Nordisk Healthcare Ag |
Proteinas conjugadas con eficacia prolongada in vivo.
|
|
DE102008051834A1
(de)
|
2008-10-17 |
2010-04-22 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
|
DE102008053048A1
(de)
|
2008-10-24 |
2010-04-29 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
|
HUE068164T2
(hu)
|
2008-10-17 |
2024-12-28 |
Sanofi Aventis Deutschland |
Egy inzulin és egy GLP-1 agonista kombinációja
|
|
DE102009038210A1
(de)
|
2009-08-20 |
2011-03-03 |
Sanofi-Aventis Deutschland Gmbh |
Kombination von einem Insulin und einem GLP-1-Agonisten
|
|
WO2010054326A2
(en)
|
2008-11-07 |
2010-05-14 |
The General Hospital Corporation |
C-terminal fragments of glucagon-like peptide-1 (glp-1)
|
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
|
SMT201700189T1
(it)
*
|
2008-12-10 |
2017-05-08 |
Glaxosmithkline Llc |
Composizioni farmaceutiche di albiglutide
|
|
JP5635530B2
(ja)
|
2008-12-15 |
2014-12-03 |
ジーランド ファーマ アクティーゼルスカブ |
グルカゴン類似体
|
|
KR20150116912A
(ko)
|
2008-12-15 |
2015-10-16 |
질랜드 파마 에이/에스 |
글루카곤 유사체
|
|
US8680049B2
(en)
|
2008-12-15 |
2014-03-25 |
Zealand Pharma A/S |
Glucagon analogues
|
|
ES2439499T3
(es)
|
2008-12-15 |
2014-01-23 |
Zealand Pharma A/S |
Análogos de glucagón
|
|
CN102292349B
(zh)
|
2009-01-22 |
2016-04-13 |
诺沃—诺迪斯克保健股份有限公司 |
稳定的生长激素化合物
|
|
WO2011003822A2
(de)
*
|
2009-07-06 |
2011-01-13 |
Sanofi-Aventis Deutschland Gmbh |
Insulinzubereitungen enthaltend methionin
|
|
US20120232002A1
(en)
*
|
2009-07-06 |
2012-09-13 |
Sanofi-Aventis Deutschland Gmbh |
Slow-acting insulin preparations
|
|
PT2454282E
(pt)
|
2009-07-13 |
2015-06-23 |
Zealand Pharma As |
Análogos de glucagão acilados
|
|
CN101987868B
(zh)
*
|
2009-07-30 |
2013-09-04 |
江苏豪森医药集团有限公司 |
Glp-1类似物的衍生物或其可药用盐和用途
|
|
CN102612376A
(zh)
|
2009-08-06 |
2012-07-25 |
诺沃-诺迪斯克保健股份有限公司 |
具有延长的体内功效的生长激素
|
|
CN102482312A
(zh)
|
2009-08-26 |
2012-05-30 |
赛诺菲 |
新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
|
|
WO2011048614A2
(en)
|
2009-10-22 |
2011-04-28 |
Cadila Healthcare Limited |
Short chain peptidomimetics based orally active glp-1 agonist and glucagon receptor antagonist
|
|
JP2011105609A
(ja)
*
|
2009-11-13 |
2011-06-02 |
Sanofi-Aventis Deutschland Gmbh |
メトホルミンへの付加療法を含む２型糖尿病の治療方法
|
|
CA2780460C
(en)
|
2009-11-13 |
2018-09-04 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
|
|
RS52629B2
(sr)
|
2009-11-13 |
2019-11-29 |
Sanofi Aventis Deutschland |
Liksisenatid kao dodatna terapija insulin glarginu i metforminu za lečenje dijabetesa tipa 2
|
|
SG10201500871TA
(en)
|
2009-11-13 |
2015-04-29 |
Sanofi Aventis Deutschland |
Pharmaceutical composition comprising a glp-1 agonist and methionine
|
|
PL2324853T3
(pl)
|
2009-11-13 |
2016-01-29 |
Sanofi Aventis Deutschland |
Liksysenatyd jako dodatek do metforminy w leczeniu cukrzycy typu 2
|
|
AU2009238272B2
(en)
*
|
2009-11-13 |
2014-05-08 |
Sanofi-Aventis Deutschland Gmbh |
Method of treatment of diabetes type 2 comprising add-on therapy to metformin
|
|
DE102010011919A1
(de)
|
2010-03-18 |
2011-09-22 |
Sanofi-Aventis Deutschland Gmbh |
Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
|
|
BR112012018104A2
(pt)
|
2010-01-20 |
2017-10-17 |
Zeland Pharma As |
tratamento de doenças cardíacas
|
|
MX345736B
(es)
|
2010-01-22 |
2017-02-14 |
Novo Nordisk Healthcare Ag |
Hormonas de crecimiento con eficacia in vivo prolongada.
|
|
US9211342B2
(en)
|
2010-01-22 |
2015-12-15 |
Novo Nordisk Healthcare Ag |
Stable growth hormone compounds resistant to proteolytic degradation
|
|
CN102770440A
(zh)
|
2010-03-01 |
2012-11-07 |
诺沃—诺迪斯克有限公司 |
纯化肽的制备性rp-hplc方法
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2555791B1
(en)
|
2010-04-09 |
2017-11-01 |
Sinai Health System |
Methods for treating disorders of the gastrointestinal tract using a glp-1 agonist
|
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
|
BR112012027759A2
(pt)
|
2010-04-27 |
2017-08-15 |
Zealand Pharma As |
Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
|
|
WO2011140176A1
(en)
|
2010-05-04 |
2011-11-10 |
Glaxosmithkline Llc |
Methods for treating or preventing cardiovascular disorders and providing cardiovascular protection
|
|
AU2011202239C1
(en)
|
2010-05-19 |
2017-03-16 |
Sanofi |
Long-acting formulations of insulins
|
|
EP2389945A1
(en)
|
2010-05-28 |
2011-11-30 |
Sanofi-Aventis Deutschland GmbH |
Pharmaceutical composition comprising AVE0010 and insulin glargine
|
|
CN101891823B
(zh)
*
|
2010-06-11 |
2012-10-03 |
北京东方百泰生物科技有限公司 |
一种Exendin-4及其类似物融合蛋白
|
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
AR081975A1
(es)
|
2010-06-23 |
2012-10-31 |
Zealand Pharma As |
Analogos de glucagon
|
|
MA34383B1
(fr)
|
2010-06-24 |
2013-07-03 |
Zealand Pharma As |
Analogues de glucagon
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
RS55378B1
(sr)
|
2010-08-30 |
2017-03-31 |
Sanofi Aventis Deutschland |
Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
|
|
US9040481B2
(en)
|
2010-11-02 |
2015-05-26 |
The General Hospital Corporation |
Methods for treating steatotic disease
|
|
RU2600440C3
(ru)
|
2010-12-16 |
2021-12-10 |
Ново Нордиск А/С |
Твердые композиции, содержащие агонист glp-1 и соль n-(8-(2-гидроксибензоил)амино)каприловой кислоты
|
|
RU2572703C2
(ru)
|
2011-02-02 |
2016-01-20 |
Санофи-Авентис Дойчланд Гмбх |
Предотвращение гипогликемии у пациентов с сахарным диабетом 2 типа
|
|
WO2012120053A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
EP2683703B1
(de)
|
2011-03-08 |
2015-05-27 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
WO2012120056A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
US8846666B2
(en)
|
2011-03-08 |
2014-09-30 |
Sanofi |
Oxathiazine derivatives which are substituted with benzyl or heteromethylene groups, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120051A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2683705B1
(de)
|
2011-03-08 |
2015-04-22 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
US8901114B2
(en)
|
2011-03-08 |
2014-12-02 |
Sanofi |
Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
|
|
US20120277147A1
(en)
|
2011-03-29 |
2012-11-01 |
Sanofi-Aventis Deutschland Gmbh |
Prevention of hypoglycaemia in diabetes mellitus type 2 patients
|
|
CA2832811A1
(en)
|
2011-04-12 |
2012-10-18 |
Novo Nordisk A/S |
Double-acylated glp-1 derivatives
|
|
US8735349B2
(en)
|
2011-05-13 |
2014-05-27 |
Sanofi-Aventis Deutschland Gmbh |
Method for improving glucose tolerance in a diabetes type 2 patient of younger than 50 years and having postprandial plasma glucose concentration of at least 14 mmol/L
|
|
BR112013029062A2
(pt)
|
2011-05-13 |
2016-11-29 |
Sanofi Aventis Deutschland |
lixisenatida e metformina para o tratamento de diabetes tipo 2
|
|
US9821032B2
(en)
|
2011-05-13 |
2017-11-21 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
|
|
US20130040878A1
(en)
|
2011-05-13 |
2013-02-14 |
Sanofi-Aventis Deutschland Gmbh |
Pharmaceutical combination for use in the treatment of diabetes type 2 patients
|
|
EP2729157B1
(en)
|
2011-07-06 |
2019-01-16 |
The General Hospital Corporation |
A pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1) for use in treatment
|
|
BR112014004726A2
(pt)
|
2011-08-29 |
2017-04-04 |
Sanofi Aventis Deutschland |
combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
|
|
TWI559929B
(en)
|
2011-09-01 |
2016-12-01 |
Sanofi Aventis Deutschland |
Pharmaceutical composition for use in the treatment of a neurodegenerative disease
|
|
EP2567959B1
(en)
|
2011-09-12 |
2014-04-16 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2760862B1
(en)
|
2011-09-27 |
2015-10-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2763691A1
(en)
|
2011-10-04 |
2014-08-13 |
Sanofi-Aventis Deutschland GmbH |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the biliary tract
|
|
US20130096060A1
(en)
|
2011-10-04 |
2013-04-18 |
Jens Stechl |
Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
|
|
JP6329487B2
(ja)
|
2011-10-28 |
2018-05-23 |
サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
２型糖尿病の治療プロトコル
|
|
AU2012331053A1
(en)
|
2011-11-03 |
2014-05-29 |
Zealand Pharma A/S |
GLP-1 receptor agonist peptide gastrin conjugates
|
|
CN103087174B
(zh)
*
|
2011-11-03 |
2015-11-18 |
华东师范大学 |
一种glp-1衍生物dlg3312及其固相化学合成方法
|
|
JP2015500823A
(ja)
|
2011-12-09 |
2015-01-08 |
ノヴォ ノルディスク アー／エス |
Ｇｌｐ−１アゴニスト
|
|
PE20142113A1
(es)
|
2011-12-23 |
2014-12-03 |
Zealand Pharma As |
Analogos de glucagon
|
|
US10933120B2
(en)
|
2012-03-22 |
2021-03-02 |
Novo Nordisk A/S |
Compositions of GLP-1 peptides and preparation thereof
|
|
ES2715308T3
(es)
|
2012-03-22 |
2019-06-03 |
Novo Nordisk As |
Composiciones que comprenden un agente de suministro y su preparación
|
|
AR090937A1
(es)
|
2012-05-03 |
2014-12-17 |
Zealand Pharma As |
Compuestos agonista duales de gip-glp-1 y metodos para usarlos
|
|
CN104540850B
(zh)
|
2012-05-03 |
2018-05-18 |
西兰制药公司 |
胰高血糖素样肽2(glp-2)类似物
|
|
ES2871328T3
(es)
|
2012-06-20 |
2021-10-28 |
Novo Nordisk As |
Formulación de comprimido que comprende un péptido y un agente de suministro
|
|
BR112015001451B1
(pt)
|
2012-07-23 |
2022-03-29 |
Zealand Pharma A/S |
Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável
|
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
|
IN2015DN03795A
(enExample)
|
2012-10-24 |
2015-10-02 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
|
|
WO2014077575A1
(ko)
*
|
2012-11-13 |
2014-05-22 |
다인바이오 주식회사 |
덱에이 효소반응으로 조제한 항비만 및 항당뇨 효능을 갖는 한천 유래 네오아가로올리고당 복합 조성물
|
|
KR20140088837A
(ko)
*
|
2013-01-03 |
2014-07-11 |
한미약품 주식회사 |
Ｎ-말단 전하가 변형된 인슐린 분비 펩티드 유도체
|
|
TWI641381B
(zh)
|
2013-02-04 |
2018-11-21 |
法商賽諾菲公司 |
胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
|
|
ES2709339T3
(es)
|
2013-04-03 |
2019-04-16 |
Sanofi Sa |
Tratamiento de la diabetes mellitus mediante formulaciones de insulinas de acción prolongada
|
|
CN105120887A
(zh)
|
2013-04-05 |
2015-12-02 |
诺和诺德保健股份有限公司 |
生长激素化合物制剂
|
|
AU2014261336B2
(en)
|
2013-05-02 |
2019-02-28 |
Novo Nordisk A/S |
Oral dosing of GLP-1 compounds
|
|
US9498534B2
(en)
|
2013-07-04 |
2016-11-22 |
Novo Nordisk A/S |
Derivatives of GLP-1 like peptides, and uses thereof
|
|
GB201315335D0
(en)
|
2013-08-29 |
2013-10-09 |
Of Singapore |
Amino diacids containing peptide modifiers
|
|
MX368436B
(es)
|
2013-10-17 |
2019-10-03 |
Zealand Pharma As |
Analogos de glucagon acilados.
|
|
US9988429B2
(en)
*
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
|
AU2014347668A1
(en)
|
2013-11-05 |
2016-05-19 |
Ben-Gurion University Of The Negev Research And Development Authority |
Compounds for the treatment of diabetes and disease complications arising from same
|
|
CA2929459C
(en)
|
2013-11-06 |
2022-05-03 |
Zealand Pharma A/S |
Gip-glp-1 dual agonist compounds and methods
|
|
KR102310392B1
(ko)
|
2013-11-06 |
2021-10-13 |
질랜드 파마 에이/에스 |
글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
|
|
CN103613657B
(zh)
*
|
2013-11-28 |
2016-01-13 |
孙玉琨 |
缩短肽链的Exendin4及其基因工程应用
|
|
EP3091995B1
(en)
|
2014-01-09 |
2024-03-20 |
Sanofi |
Stabilized pharmaceutical formulations of insulin aspart
|
|
SG11201604706TA
(en)
|
2014-01-09 |
2016-07-28 |
Sanofi Sa |
Stabilized pharmaceutical formulations of insulin aspart
|
|
WO2015104311A1
(en)
|
2014-01-09 |
2015-07-16 |
Sanofi |
Stabilized glycerol free pharmaceutical formulations of insulin analogues and/or insulin derivatives
|
|
KR101768446B1
(ko)
*
|
2014-03-21 |
2017-08-17 |
애니젠 주식회사 |
신규한 엑세나타이드 유사체 및 그의 용도
|
|
ES2883345T3
(es)
|
2014-10-29 |
2021-12-07 |
Zealand Pharma As |
Compuestos agonistas del GIP y métodos
|
|
TWI758239B
(zh)
|
2014-12-12 |
2022-03-21 |
德商賽諾菲阿凡提斯德意志有限公司 |
甘精胰島素/利司那肽固定比率配製劑
|
|
TWI706779B
(zh)
|
2015-01-16 |
2020-10-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
小兒第２型糖尿病病患之治療
|
|
TWI748945B
(zh)
|
2015-03-13 |
2021-12-11 |
德商賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患治療
|
|
TW201705975A
(zh)
|
2015-03-18 |
2017-02-16 |
賽諾菲阿凡提斯德意志有限公司 |
第２型糖尿病病患之治療
|
|
WO2016151018A1
(en)
|
2015-03-24 |
2016-09-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method and pharmaceutical composition for use in the treatment of diabetes
|
|
PL3283507T3
(pl)
|
2015-04-16 |
2020-05-18 |
Zealand Pharma A/S |
Acylowany analog glukagonu
|
|
CA3043151A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
|
EP4424362A3
(en)
|
2017-06-16 |
2024-11-27 |
Zealand Pharma A/S |
Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
|
|
FR3082426A1
(fr)
|
2018-06-14 |
2019-12-20 |
Adocia |
Compositions sous forme d'une solution aqueuse injectable comprenant au moins de l'insuline humaine a21g et un suppresseur de glucagon a action prandiale
|
|
US10610572B2
(en)
|
2017-07-27 |
2020-04-07 |
Adocia |
Compositions in the form of an injectable aqueous solution including at least human insulin A21G and a glucagon suppressor with prandial action
|
|
EP3474820B1
(en)
|
2017-08-24 |
2024-02-07 |
Novo Nordisk A/S |
Glp-1 compositions and uses thereof
|
|
BR112020014624A2
(pt)
|
2018-02-02 |
2020-12-08 |
Novo Nordisk A/S |
Composições sólidas compreendendo agonista de glp-1, sal de ácido n-(8-(2-hidroxibenzoil) amino)caprílico e lubrificante
|
|
DK3774838T3
(da)
|
2018-04-10 |
2022-10-31 |
Sanofi Aventis Deutschland |
Lixisenatidsyntese med capping
|
|
WO2019197466A1
(en)
|
2018-04-10 |
2019-10-17 |
Sanofi-Aventis Deutschland Gmbh |
Method for cleavage of solid phase-bound peptides from the solid phase
|
|
FR3083700B1
(fr)
|
2018-07-13 |
2021-03-12 |
Adocia |
Formulation thermostable d'insuline humaine a21g
|
|
EP3628682A1
(en)
|
2018-09-28 |
2020-04-01 |
Zealand Pharma A/S |
Formulations of glucagon-like-peptide-2 (glp-2) analogues
|
|
EP3628683A1
(en)
|
2018-09-28 |
2020-04-01 |
Zealand Pharma A/S |
Formulations of glucagon-like-peptide-2 (glp-2) analogues
|
|
TWI799680B
(zh)
*
|
2019-01-29 |
2023-04-21 |
美商美國禮來大藥廠 |
製備gip/glp1雙重促效劑之方法
|
|
CN109721653B
(zh)
*
|
2019-03-05 |
2023-02-03 |
嘉兴学院 |
一种胰高血糖素样肽-1片段类似物及其应用
|
|
US20210093698A1
(en)
|
2019-09-13 |
2021-04-01 |
Sanofi |
Treatment of type 2 diabetes mellitus
|
|
EP3858373A1
(en)
|
2020-01-31 |
2021-08-04 |
Adocia |
Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
|
|
PE20230819A1
(es)
|
2020-02-18 |
2023-05-19 |
Novo Nordisk As |
Composiciones y usos de glp-1
|
|
EP3915571A1
(en)
|
2020-05-29 |
2021-12-01 |
Adocia |
Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
|
|
EP3915572A1
(en)
|
2020-05-29 |
2021-12-01 |
Adocia |
Pharmaceutical composition in the form of an injectable aqueous solution including at least a rapid acting insulin analog and a glucagon suppressor with prandial action
|
|
AU2021397877A1
(en)
*
|
2020-12-11 |
2023-07-06 |
Ip2Ipo Innovations Limited |
Novel compounds
|
|
EP4129324A1
(en)
|
2021-08-02 |
2023-02-08 |
Adocia |
Compositions comprising at least an amylin receptor agonist and a glp-1 receptor agonist
|
|
TW202327643A
(zh)
|
2021-09-10 |
2023-07-16 |
丹麥商西蘭製藥公司 |
包含類升糖素肽2(glp-2)類似物之組合物之調配方法
|
|
JP2024544418A
(ja)
|
2021-12-23 |
2024-11-29 |
ジーランド・ファルマ・アー／エス |
グルカゴン様ペプチド２（ｇｌｐ－２）アナログを合成するためのプロセス
|
|
WO2024068848A1
(en)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Methods for treating obesity
|
|
WO2024123812A1
(en)
|
2022-12-05 |
2024-06-13 |
Shattuck Labs, Inc. |
Fusion proteins for the treatment of cardiometabolic diseases
|
|
GB202308304D0
(en)
|
2023-06-02 |
2023-07-19 |
Univ Ulster |
A fusion peptide for activation of the apj and/or glp-1 receptors
|
|
KR20240176455A
(ko)
|
2023-06-15 |
2024-12-24 |
노보 노르디스크 에이/에스 |
시클로덱스트린을 포함하는 약학적 제형
|
|
WO2025141129A1
(en)
|
2023-12-28 |
2025-07-03 |
Zealand Pharma A/S |
Formulations of glucagon-like-peptide 2 (glp-2) analogues and their uses
|